Opinion|Videos|September 24, 2024
Overview of FINEARTS-HF Trial
Author(s)Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, discusses the FINEARTS-HF trial presented at European Society of Cardiology Congress 2024, highlighting its objective to evaluate finerenone in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, the randomized design, and results indicating a reduction in worsening HF events compared with placebo.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 on the FINEARTS-HF trial evaluating finerenone use among patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF.
- What was the objective of this study?
- How was this study designed, and what methodology was used?
- What results were presented?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5
